Cargando…
Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
BACKGROUND: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174118/ https://www.ncbi.nlm.nih.gov/pubmed/21835042 http://dx.doi.org/10.1186/1477-7819-9-88 |
_version_ | 1782212029257351168 |
---|---|
author | Consorti, Fabrizio Di Tanna, Gianluca Milazzo, Francesca Antonaci, Alfredo |
author_facet | Consorti, Fabrizio Di Tanna, Gianluca Milazzo, Francesca Antonaci, Alfredo |
author_sort | Consorti, Fabrizio |
collection | PubMed |
description | BACKGROUND: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a subgroup of women surgically treated for papillary thyroid cancer that may benefit from more careful breast cancer screening. METHODS: A total of 101 women surgically treated for papillary thyroid cancer from 1996 to 2009 with subsequent follow-up were interviewed by phone regarding personal risk factors and lifestyle habits. Only 75 questionnaires could be evaluated due to a 25.7% rate of patients not retrieved or refusing the interview. Data analysis was performed using a multivariate logistic model. RESULTS: The standardised incidence ratio (SIR) for breast cancer was 3.58 (95% IC 1.14 - 8.37). Our data suggest a protective effect of multiparity on the development of a SPM of the breast (O.R. 0.15; 95% IC 0.25 - 0.86). Significant associations were not found with other known risk factors including Body Mass Index (BMI), age at first tumour, concurrent metabolic diseases, smoking, physical activity and familiarity. CONCLUSIONS: This study confirms that a higher incidence of SPM of the breast is observed in women treated for papillary thyroid cancer. Additionally, this risk is increased by nulliparity, thus a strict breast screening program for nulliparous women treated for thyroid cancer may be advisable. |
format | Online Article Text |
id | pubmed-3174118 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31741182011-09-16 Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer Consorti, Fabrizio Di Tanna, Gianluca Milazzo, Francesca Antonaci, Alfredo World J Surg Oncol Research BACKGROUND: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a subgroup of women surgically treated for papillary thyroid cancer that may benefit from more careful breast cancer screening. METHODS: A total of 101 women surgically treated for papillary thyroid cancer from 1996 to 2009 with subsequent follow-up were interviewed by phone regarding personal risk factors and lifestyle habits. Only 75 questionnaires could be evaluated due to a 25.7% rate of patients not retrieved or refusing the interview. Data analysis was performed using a multivariate logistic model. RESULTS: The standardised incidence ratio (SIR) for breast cancer was 3.58 (95% IC 1.14 - 8.37). Our data suggest a protective effect of multiparity on the development of a SPM of the breast (O.R. 0.15; 95% IC 0.25 - 0.86). Significant associations were not found with other known risk factors including Body Mass Index (BMI), age at first tumour, concurrent metabolic diseases, smoking, physical activity and familiarity. CONCLUSIONS: This study confirms that a higher incidence of SPM of the breast is observed in women treated for papillary thyroid cancer. Additionally, this risk is increased by nulliparity, thus a strict breast screening program for nulliparous women treated for thyroid cancer may be advisable. BioMed Central 2011-08-12 /pmc/articles/PMC3174118/ /pubmed/21835042 http://dx.doi.org/10.1186/1477-7819-9-88 Text en Copyright ©2011 Consorti et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Consorti, Fabrizio Di Tanna, Gianluca Milazzo, Francesca Antonaci, Alfredo Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
title | Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
title_full | Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
title_fullStr | Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
title_full_unstemmed | Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
title_short | Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
title_sort | nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174118/ https://www.ncbi.nlm.nih.gov/pubmed/21835042 http://dx.doi.org/10.1186/1477-7819-9-88 |
work_keys_str_mv | AT consortifabrizio nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer AT ditannagianluca nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer AT milazzofrancesca nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer AT antonacialfredo nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer |